Navigating Psychedelics for Clinicians and Wellness Practitioners
Open Learning
Live
Sep 25, 2023
1,750
–
1,800
USD
Online
9 Weeks
Awarded: Certificate of Completion
Description
Everything professionals need to know about psychedelics and psychedelic integration
Navigating Psychedelics: For Clinicians and Wellness Practitioners - Australia is a transformative educational program for clinicians and wellness practitioners that provides an in-depth understanding of psychedelic substances, their history, therapeutic potential, and responsible use.
This course is designed as a general introduction to the field of psychedelics in an Australian context. It is designed for Clinicians and Wellness Practitioners.
This course will provide essential background knowledge for people who are interested in progressing their career in the field and wish to do the advanced clinical skills training in order to work in clinical trials and other settings where psychedelics are used for therapeutic purposes.
The psychedelic landscape in Australia is undergoing a rapid transformation, marking a historic milestone in the world of therapeutic treatments. From July 2023, the Therapeutic Goods Administration (TGA) has approved the prescription of MDMA and psilocybin for specific mental health conditions, making Australia the first country to legalize the prescription of psychedelic drugs for therapeutic use.
This groundbreaking decision was founded on compassionate grounds and available scientific evidence revealing the efficacy of MDMA and psilocybin in treating treatment-resistant depression and post-traumatic stress disorder. The TGA has imposed strict regulations to ensure safe administration. Only TGA-approved psychiatrists are allowed to prescribe these drugs, and they are reserved for patients who have been diagnosed with approved conditions and have not responded to conventional treatments.
This move represents a significant stride towards advancing mental health treatments in Australia. Nonetheless, it is crucial to recognize that psychedelic therapies are still in the early stages of clinical research, and further studies are imperative to fully comprehend their safety and effectiveness. For this same reason, education around how to safely use these substances is paramount.
Excitingly, the Australian government is considering policy changes to facilitate more extensive psychedelic research and improve accessibility to psychedelic therapy.
Navigating Psychedelics: For Clinicians and Wellness Practitioners - Australia is a transformative educational program for clinicians and wellness practitioners that provides an in-depth understanding of psychedelic substances, their history, therapeutic potential, and responsible use.
This course is designed as a general introduction to the field of psychedelics in an Australian context. It is designed for Clinicians and Wellness Practitioners.
This course will provide essential background knowledge for people who are interested in progressing their career in the field and wish to do the advanced clinical skills training in order to work in clinical trials and other settings where psychedelics are used for therapeutic purposes.
The psychedelic landscape in Australia is undergoing a rapid transformation, marking a historic milestone in the world of therapeutic treatments. From July 2023, the Therapeutic Goods Administration (TGA) has approved the prescription of MDMA and psilocybin for specific mental health conditions, making Australia the first country to legalize the prescription of psychedelic drugs for therapeutic use.
This groundbreaking decision was founded on compassionate grounds and available scientific evidence revealing the efficacy of MDMA and psilocybin in treating treatment-resistant depression and post-traumatic stress disorder. The TGA has imposed strict regulations to ensure safe administration. Only TGA-approved psychiatrists are allowed to prescribe these drugs, and they are reserved for patients who have been diagnosed with approved conditions and have not responded to conventional treatments.
This move represents a significant stride towards advancing mental health treatments in Australia. Nonetheless, it is crucial to recognize that psychedelic therapies are still in the early stages of clinical research, and further studies are imperative to fully comprehend their safety and effectiveness. For this same reason, education around how to safely use these substances is paramount.
Excitingly, the Australian government is considering policy changes to facilitate more extensive psychedelic research and improve accessibility to psychedelic therapy.
